{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-23-000119","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.076043+00:00","generated_at":"2026-06-08T21:29:33.230159+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio partners with Celest for SENTI-301A development in China; up to $156M milestones","bullets":["Celest to lead clinical development and manufacturing of SENTI-301A in mainland China; first patient expected 1H 2024.","Senti Bio retains all commercialization rights outside mainland China, Hong Kong, Macau, and Taiwan.","Senti eligible for up to $156M in milestone payments plus tiered royalties on potential sales.","SENTI-301A is an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing hepatocellular carcinoma.","Pilot trial will enroll 9 patients across two dose cohorts to assess safety and efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-23-000119","json":"https://secwatch.observer/filing/0001854270-23-000119.json","markdown":"https://secwatch.observer/filing/0001854270-23-000119.md","text":"https://secwatch.observer/filing/0001854270-23-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/0001854270-23-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/snti-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:29:33.230159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64d3312d14328ac952c80b2938088032c47419a2","claim":"Senti Biosciences, Inc. entered into Collaboration and Option Agreement with Celest Therapeutics (Shanghai) Co. Ltd. (effective 2023-11-06).","evidence_excerpt":"On November 6, 2023, Senti Biosciences, Inc. (the “ Company ”) entered into a Collaboration and Option Agreement (the “ Agreement ”) with Celest Therapeutics (Shanghai) Co. Ltd.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427023000119/0001854270-23-000119-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Celest Therapeutics (Shanghai) Co. Ltd."},{"label":"Effective","value":"2023-11-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}